ZDHHC5 has been reported to mediate palmitoylation in TP53-mutant gliomas and drives malignant development and progression (Chen et al., 2017). Similarly, ZDHHC5 expression was increased in the TP53 mutant LUAD group (Figure 2D). As TP53 mutation is one of the PI’s molecular characters, this result consists with the high expression of ZDHHC5 in PI subtypes. Therapies targeting the palmitoylation process may be a potential strategy in treatments of TP53 mutation LUAD patients.
